HIV screening of the blood supply in developed and developing countries

AIDS Reviews

Volumn 3, Issue 1, 2001, Pages 24-35

  Chamberland, M E ^a   Lackritz, E M ^a   Busch, M P ^a  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

Author keywords

Blood transfusion; NAT; PCR; Serology; Transmission

Indexed keywords

ANEMIA; BLOOD BANK; BLOOD DONOR; BLOOD EXAMINATION; BLOOD TRANSFUSION; CELL COMPOSITION; CLINICAL TRIAL; CONTAMINATION; DEVELOPED COUNTRY; DEVELOPING COUNTRY; EARLY DIAGNOSIS; GENE AND NUCLEIC ACID PARAMETERS; HEALTH CARE COST; HEALTH CARE MANAGEMENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; POLYMERASE CHAIN REACTION; RELIABILITY; RESOURCE ALLOCATION; REVIEW; RISK ASSESSMENT; SAFETY; SCREENING TEST; SEROLOGY; SOCIAL SUPPORT; STAFF TRAINING; VIRUS INACTIVATION; VIRUS TRANSMISSION;

EID: 0035037152     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (101)

1. HIV-1 infection incidence among persons with hemophilia in the United States and western Europe, 1978-1990. Multicenter Hemophilia Cohort Study
2. Risk of human immunodeficiency virus (HIV) transmission by blood transfusions before the implementation of HIV-1 antibody screening
3. Public Health Service inter-agency guidelines for screening donors of blood, plasma, organs, tissues, and semen for evidence of hepatitis B and hepatitis C
4. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light
5. Inactivation of viruses, bacteria, protozoa, and leukocytes in platelet concentrates
6. Prevention of HIV transmission by blood transfusion in the developing world: Achievements and continuing challenges
7. Cost-effectiveness of Uganda blood program
8. Centralized HIV screening service: An operational strategy for improving blood safety in Oyo State - Nigeria
9. The U.S. Blood Supply System
10. Posttransfusion hepatitis after exclusion of commercial and hepatitis-B antigen-positive donors
11. Direct oral questions to blood donors: The impact on screening for human immunodeficiency virus
12. Screening potential blood donors at risk for human immunodeficiency virus
13. Impact of explicit questions about high-risk activities on donor attitudes and donor deferral patterns. Results in two community blood centers
14. Effects of oral donor questioning about high-risk behaviors for human immunodeficiency virus infection
15. Demographic characteristics and prevalence of serologic markers among donors who use the confidential unit exclusion process: The Retrovirus Epidemiology Donor Study
16. The effectiveness of the confidential unit exclusion option
17. Status of Confidential Unit Exclusion (CUE), America's Blood Centers survey, November 1999
18. Measures to decrease the risk of acquired immunodeficiency syndrome transmission by blood transfusion. Evidence of volunteer blood donor cooperation
19. Patterns of blood donations among individuals at risk for AIDS, 1984
20. Human immunodeficiency virus type 1-infected blood donors: Behavioral characteristics and reasons for donation. The HIV Blood Donor Study Group
21. Human immunodeficiency virus type 1-infected blood donors: Epidemiologic, laboratory, and donation characteristics
22. Prevalence rates and risk behaviors among U.S. HIV positive blood donors
23. Why do HIV screening questions miss high-risk blood donors
24. Estimates of infectious disease risk factors in US blood donors. Retrovirus Epidemiology Donor Study
25. HIV testing in blood banks
26. Testing for antibodies to human immunodeficiency virus type 2 in the United States
27. Interpretation and use of the Western blot assay for serodiagnosis of human immunodeficiency virus type 1 infections
28. HIV counseling, testing, and referral, draft guidelines; Notice
29. Frequency of human immunodeficiency virus (HIV) infection among contemporary anti-HIV-1 and anti-HIV-1/2 supplemental test-indeterminate blood donors
30. HIV-1: Absence of infection in subjects with indeterminate Western blot
31. Long-term follow-up of blood donors with indeterminate human immunodeficiency virus type 1 results on Western blot
32. False-positive HIV-1 test results in a low-risk screening setting of voluntary blood donation
33. Identification and characterization of an HIV-2 antibody-positive blood donor in the United States
34. Human immunodeficiency virus type 2 infection in the United States. Epidemiology, diagnosis, and public health implications
35. The emerging genetic diversity of HIV. The importance of global surveillance for diagnostics, research, and prevention
36. Sensitivity of United States HIV antibody tests for detection of HIV-1 group O infections
37. Surveillance for human immunodeficiency virus type 1 group O infections in the United States
38. Human immunodeficiency virus (HIV) subtype surveillance of African-born persons at risk for group O and group N HIV infections in the United States
39. Presence of human immunodeficiency virus (HIV) type 1, group M, non-B subtypes, Bronx, New York: A sentinel site for monitoring HIV genetic diversity in the United States
40. Surveillance of HIV-1 genetic subtypes and diversity in the U.S. blood supply
41. Increasing diversity of HIV-1M serotypes in French blood donors over a 10-year period (1985-1995). Retrovirus Study Group of the French Society of Blood Transfusion
42. Lack of screening test sensitivity during HIV-1 non-subtype B seroconversions
43. Nucleic acid amplification testing of blood donors for transfusion-transmitted infectious diseases: Report of the Interorganizational Task Force on Nucleic Acid Amplification Testing of Blood Donors
44. NAT and blood safety: What is the paradigm?
45. HIV, HBV and HCV: New developments related to transfusion safety
46. Direct HIV testing in blood donations: Variation of the yield with detection threshold and pool size
47. U.S. Public Health Service guidelines for testing and counseling blood and plasma donors for human immunodeficiency virus type 1 antigen
48. Time course of detection of viral and serologic markers preceding human immunodeficiency virus type 1 seroconversion: Implications for screening of blood and tissue donors
49. Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States
50. NAT of the United States and Canadian blood supply
51. NAT may replace HIV-1p24 antigen testing.
52. Delayed donations in repeat blood donors who HIV seroconvert may explain low p24 antigen (Ag) yield
53. The efficacy of HIV p24 antigen screening of US blood donors: Projections versus reality
54. US blood donor screening with p24 antigen (Ag); One year experience
55. Residues of NAT: Questions and commentary
56. Failure of routine HIV-1 tests in a case involving transmission with preseroconversion blood components during the infectious window period
57. Summary of a workshop on the implementation of NAT to screen donors of blood and plasma for viruses
58. Testing of individual blood donations for HCV RNA reduces the residual risk of transfusion-transmitted HCV infection
59. Trends in incidence and prevalence of major transfusion-transmissible viral infections in U.S. blood donors, 1991 to 1996. Retrovirus Epidemiology Donor Study (REDS)
60. Trends in HIV prevalence among childbearing women in the United States, 1989-1994
61. Prevalence of HIV infection in the United States, 1984 to 1992
62. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes
63. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study
64. Results of national testing of U.S. blood donations for HIV-1 p24 antigen
65. Safe blood transfusions in Africa
66. Essential laboratory services in blood transfusion
67. HIV transmission through blood, tissues, and organs
68. Risk of transfusion-associated HIV transmission in Kinshasa, Zaire
69. Evaluation of HIV testing of the blood supply in Kenya
70. The importance of simple/rapid assays in HIV testing
71. Rapid tests for HIV antibody
72. Optimizing the delivery of HIV counseling and testing services: The Uganda experience with rapid antibody test algorithms
73. HIV seropositivity in blood donors from 1990 to 1992: Prevalence, estimation of residual risk of transfusion-related infections and epidemiology
74. Effect of blood transfusion on survival among children in a Kenyan hospital
75. Beyond blood screening: Reducing unnecessary transfusions and improving laboratory services in Cote d'Ivoire
76. Childhood anemia in Africa: To transfuse or not transfuse?
77. The association between malaria, blood transfusions, and HIV seropositivity in a pediatric population in Kinshasa, Zaire
78. The epidemiology of anemia and malaria parasitemia in western Kenya: Implications for the prevention of blood transfusion
79. Blood transfusion practices in Mwanza Region, Tanzania. Bugando Medical Centre
80. How well are hospitals preventing iatrogenic HIV? A study of the appropriateness of blood transfusions in three hospitals in the Ashanti region, Ghana
81. Prevention of HIV transmission through blood transfusion in Tanzania
82. Infectious disease markers in blood donors in northern Thailand
83. Behavioural risk factors for acquisition of HIV infection and knowledge about AIDS among male professional blood donors in Delhi
84. Secondary school students: A safer blood donor population in an urban with high HIV prevalence in east Africa
85. Blood transfusion practices and blood-banking services in a Kenyan hospital
86. Prevention of blood-borne HIV transmission using a decentralized approach in Shaba, Zaire
87. Beyond chloroquine: Implications of drug resistance for evaluating malaria therapy efficacy and treatment policy in Africa
88. Longitudinal evaluation of severely anemic children in Kenya: The effect of transfusion on mortality and hematologic recovery
89. Human immunodeficiency virus infection and other sexually transmitted diseases in developing countries: Public health importance and priorities for resource allocation